Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab
ConclusionPre-treatment PLR could serve as a valuable independent prognostic factor for ES-SCLC who receive chemotherapy and immune checkpoint inhibitors. Further, prospective studies are still needed to confirm our findings.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Nutrition | Small Cell Lung Cancer | Study